Section of Heart Failure and Transplantation Medicine; Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute; Cleveland Clinic, 9500 Euclid Ave, J3-4, Cleveland, OH, 44195, USA.
Curr Heart Fail Rep. 2024 Dec;21(6):570-579. doi: 10.1007/s11897-024-00683-9. Epub 2024 Oct 4.
Cardiac sarcoidosis and other inflammatory cardiomyopathies are disorders causing cardiac inflammation and leading to heart failure, arrythmias and cardiac arrest. Diagnosis of these entities remains challenging and multimodal. Thus, there is a growing need to develop reliable biomarkers that can aid in the diagnosis. This review aims to summarize and highlight recent findings in the field of biomarkers for cardiac sarcoidosis and inflammatory cardiomyopathy.
Multiple categories of biomarkers including novel molecules are being investigated with the latest evidence showing promising results. Some of these biomarkers are proven to be useful as diagnostic and prognostic aids in cardiac sarcoid and inflammatory cardiomyopathy. The identification of cost-effective and accurate biomarkers is useful not only for enhancing diagnostic accuracy but also for informing therapeutic decision-making processes. This advancement would facilitate the timely institution of immunosuppressive therapies, ultimately leading to improved patient outcomes.
心肌结节病和其他炎症性心肌病是导致心肌炎症并导致心力衰竭、心律失常和心脏骤停的疾病。这些疾病的诊断仍然具有挑战性，需要多模式诊断。因此，越来越需要开发能够辅助诊断的可靠生物标志物。本综述旨在总结和强调心肌结节病和炎症性心肌病生物标志物领域的最新发现。
正在研究多种类别的生物标志物，包括新型分子，最新证据表明这些标志物具有有前景的结果。其中一些生物标志物已被证明可作为心肌结节病和炎症性心肌病的诊断和预后辅助手段。确定具有成本效益和准确性的生物标志物不仅有助于提高诊断准确性，还有助于为治疗决策过程提供信息。这一进展将促进免疫抑制治疗的及时实施，最终改善患者的预后。
